Navigation Links
US Patent Allowed for Spring Action That Separates Protectus Innovative Safety Syringe From All Others

MINNEAPOLIS, July 8 /PRNewswire-FirstCall/ -- Protectus Medical Devices, Inc. (OTCQB: PTMD), developer and marketer of innovative safety medical devices, announced today it has received Notice of Allowance from the US Patent and Trademark Office on its patent application describing a spring-activated, automatic, self-sheathing Safety Syringe, a major step toward it becoming the gold standard in safety syringe devices. 

Dr. John Salstrom, CEO, said the unique spring-activation feature distinguishes the Protectus Safety Syringe and its entire line of safety needle devices from all others and, like no other, has the very real potential to significantly reduce accidental needlestick injuries automatically without any action by users. 

Jack Dillard, COO and inventor of the Protectus/SquareOne Medical Safety Syringe and its family of safety needle devices, said, "The key elements of this patent provide coverage for the spring responsible for the automatic deployment of the Protectus safety technology that keeps users, patients and other healthcare workers safe during and after use without having to perform any conscience action."

Protectus also announced today the filing of its patent application for a Safety IV Catheter/Cannula Introducer.  This device, along with the Protectus Safety Dental  Syringe (patent application previously announced), both employ the same spring-activated safety features as the Protectus Safety Syringe, as does the soon-to-be announced Protectus Safety Phlebotomy device.  All three devices will benefit significantly from the additional coverage provided by claims allowed in the new patent referenced by the above-mentioned Notice of Allowance, in addition to claims allowed for each device application.

The innovative Protectus Safety Syringe is designed to significantly reduce accidental needlestick injuries that have plagued the healthcare workplace for decades. When issued, the patent will have a lifespan of 20 years, prohibiting the use of similar designs that include a spring to automatically deploy a safety feature. This addition to the intellectual property of Protectus Medical Devices will affect and additionally protect all safety needle devices the company is developing.

For information contact JP Hervis 561-750-9800 x217 or

About Protectus Medical Devices, Inc. (formerly, E-18 Corp.)

Protectus Medical Devices, Inc. (PTMD, formerly, E-18 Corp.), operating through its wholly owned subsidiary, SquareOne Medical, Inc., develops and markets innovative safety medical percutaneous devices that, collectively, have the potential to dramatically reduce needlestick injuries for medical professionals worldwide. In the nearly $5 billion global hypodermic syringe market, the Protectus Safety Syringe, the Company's lead product, is the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of "Self-Sheathing" mandated by the U.S. Federal Government. None of the manufacturers of other devices on the market can make this claim. Protectus Medical Devices has successfully patented its automatic, self-sheathing hypodermic safety syringe product, and, based on the results of full comparison clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety Syringe) has received the required 510(k) permission from the U.S. FDA to manufacture and market the device in the U.S. More information about the Company may be found at

Forward-Looking Statements

This release contains "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. These forward-looking statements are subject to various risks and uncertainties that could cause the business and financial results of Protectus Medical Devices, Inc. to differ materially from those currently anticipated, including the risk factors identified in Protectus Medical Devices, Inc.'s filings with the Securities and Exchange Commission.

SOURCE Protectus Medical Devices, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
2. ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx
3. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
4. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
5. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
6. Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
7. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
8. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
9. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
10. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
11. New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):